Creative Medical Technology’s Phase 1/2 trial for back pain approved by IRB

Creative Medical Technology has received Institutional Review Board – IRB – approval to proceed with its clinical trial for the treatment of chronic lower back pain with its StemSpine procedure using AlloStem cell therapy. The receipt of IRB approval is a necessary step that will allow Creative Medical Technology to move forward with recruitment of its recently FDA approved Phase 1 /2 randomized, double blind, placebo controlled clinical trial to evaluate the safety, efficacy, and tolerability of CELZ-201-DDT. An IRB is an FDA-registered consortium that has been formally designated to review and monitor biomedical research involving human subjects. IRB approval is a necessary prerequisite to commencing human clinical trials.